In the News
Director Timothy "Tim" J. Shea, Jr. was noted in the article "Second Wave of Biosimilar Cases Sharpens Patent Counsel Focus," published by Managing IP.
"Biosimilar manufacturers have a lot of motivation to resolve these disputes outside of court too.
Tim Shea, director at Sterne Kessler in Washington DC, says these companies have put a lot of resources into developing biosimilars, and having certainty on when they can launch is worth it."
© Delinian Limited and its affiliated companies 2023